The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis
article
OA: bronze
CC0
⤵ 32 in-corpus citations
AI-generated summary
This study investigated the effect of the levonorgestrel-releasing intrauterine device on CA-125 serum levels in patients with endometriosis and found a reduction.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (20)
- A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study via openalex
- [Clinical significance of CA19-9 for endometriosis]. via openalex
- Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis. via openalex
- Effect of GnRH analogues on apoptosis and release of interleukin-1 and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis via openalex
- Fluctuations in CA 125 and CA 15 3 serum concentrations during spontaneous ovulatory cycles via openalex
- High concentrations of the CA-125, CA 19-9 and CA 15-3 in the peritoneal fluid between patients with and without endometriosis via openalex
- Immunohistochemical analysis of CA125, CA19–9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation via openalex
- Serum CA-125 in preoperative patients at high risk for endometriosis via openalex
- Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation. via openalex
- The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease via openalex
- Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas via openalex
- W2087512818 via openalex
- W2200427146 via openalex
- W1978677754 via openalex
- W6603012515 via openalex
- W6607846724 via openalex
- W6656330334 via openalex
- W6668890459 via openalex
- W2123134517 via openalex
- W6687377576 via openalex
Cited by (32)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- AVALIAÇÃO DE BIOMARCADORES EM MULHERES COM ENDOMETRIOSE E DOR USUÁRIAS DO IMPLANTE COM ETONOGESTREL OU SISTEMA INTRAUTERINO COM LEVONORGESTREL: ENSAIO CLÍNICO RANDOMIZADO 2022
- Avaliação de dois biomarcadores e de escores de dor pélvica crônica associada à endometriose em usuárias do implante com etonogestrel e do sistema intrauterino com levonorgestrel de 52 mg por 24 meses; e avaliação das vivências dos parceiros destas mulheres após o tratamento 2022
- Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery 2021
- Non-contraceptive Benefits of Hormonal Methods 2021
- Reviewing the role of progesterone therapy in endometriosis 2018
- Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial 2018
- Avaliação de biomarcadores em mulheres com endometriose e dor usuárias do implante liberador de etonogestrel ou sistema intrauterino liberador de levonorgestrel = Assessment of biomarkers among women with endometriosis-associated pain users of the etonogestrel-releasing contraceptive implant or 52-mg levonorgestrel releasing intrauterine system: randomized clinical trial 2018
- Tratamientos farmacológicos de la endometriosis (a excepción de la adenomiosis) 2018
- The Use of Resveratrol as an Adjuvant Treatment of Pain in Endometriosis: A Randomized Clinical Trial 2017
- Harmonization of Clinical and Laboratory Data to Improve Biomarker Discovery in Endometriosis: WERF EPHect 2017
- Hormonal therapy for endometriosis: from molecular research to bedside 2016
- Evaluation of oxidative stress markers and intra-extracellular antioxidant activities in patients with endometriosis 2016
- World Endometriosis Research Foundation Endometriosis Phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research 2014
- Hormonal Treatment for Severe Hydronephrosis Caused by Bladder Endometriosis 2014
- Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis 2013
- Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery 2013
- Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women 2012
- Surgical Therapies: Pouch of Douglas and Uterovaginal Pouch Resection for Endometriosis 2011
- Emerging indications for the levonorgestrel‐releasing intrauterine system (LNG‐IUS) 2011
- Role of Eutopic Endometrium in Pelvic Endometriosis 2011
- Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel‐releasing intrauterine device 2011
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Efeitos do sistema intra-uterino de Levonorgestrel sobre marcadores de risco cardiovascular de pacientes com endometriose: estudo comparativo com o análogo do GnRH 2009
- Levonorgestrelį išskiriančios gimdos spiralės vartojimas ginekologijoje 2009
- Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium 2009
- The levonorgestrel-releasing intrauterine system and endometriosis staging 2007
- Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1 2007
- Expressão gênica diferencial em tecido endometrial tópico e lesões endometrióticas 2007
- Avaliação das dosagens das interleucinas 12 e 18 no sangue e no fluido peritoneal de pacientes com endometriose pélvica 2007
- Tratamento da endometriose 2006
- 10.1016/s0246-1064(17)67531-5 2000
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:15:18.313808+00:00
License: CC0
· commercial use OK